Biology textbooks tend to describe cell identity as a one-way trip. A stem cell becomes a specialized cell, and that is the end of the story. The lining of the human intestine has never fully obeyed that rule, and researchers at Memorial Sloan Kettering Cancer Center have now identified a protein that appears to govern the exception.
The protein is ZFP36L2, an RNA-binding molecule the team describes as a molecular switch connecting the gut's damage-sensing system to a cell's ability to change what it is. When intestinal stem cells are wiped out by inflammation, infection, or injury, mature specialized cells can revert to a stem-like state and rebuild the stem cell pool. ZFP36L2 makes that reversal possible.
The catch is severe. Colorectal cancer cells appear to hijack the same program to establish tumors in distant organs. The study was published in Nature on August 5.
A Dimmer Switch That Locks Cells Into Their Adult Jobs
The gut lining is among the most punishing environments in the body. Digestion constantly strips cells away, and a population of intestinal stem cells replaces them.
Under normal conditions, as those replacement cells mature into absorptive, mucus-producing, and other specialized types, ZFP36L2 activity gradually falls. The MSK team describes it as a dimmer switch that helps lock cells into their adult identities.
Injury flips the logic. When too many stem cells are lost, mature cells receive an emergency signal and reverse course, a process biologists call dedifferentiation. The researchers showed the requirement directly: mice engineered to lack intestinal ZFP36L2 could not complete the return to a stem-cell state after induced gut injury, failed to restore LGR5-positive stem cells, and could not heal properly.
"This is really a critical process that works the same way across many different tissues, allowing cells to detect damage and turn on stem cell renewal programs," said physician-scientist Karuna Ganesh, senior author of the study, in MSK's announcement.
Metastasis Looks a Lot Like a Wound
The link to cancer follows from what happens to a tumor cell that leaves home. When cells break away from a primary colorectal tumor and travel through the bloodstream, they enter a stressed, injury-like state that resembles a damaged gut cell.
To seed a new tumor in the liver or lungs, those cells need to do what the intestine does during repair: quiet the stress response and rewind into a stem-like state capable of generating many new cells.
In patient-derived colorectal cancer organoids, depleting ZFP36L2 blocked metastatic seeding and the outgrowth of LGR5-positive metastases. Lead author Qingwen Jiang, a postdoctoral researcher in the Ganesh Lab at MSK's Sloan Kettering Institute, framed the implication carefully. "Our findings suggest that if ZFP can be disrupted in metastatic cancer cells, it could compromise their ability to start new tumors in other parts of the body," she said.
The gene is already known to be mutated in 5 to 10 percent of colorectal cancers, and related proteins in the same family appear to play a similar role in other cancers, which is part of why the group considers the mechanism broadly relevant.
The Complication That Makes This Harder Than It Sounds
Losing ZFP36L2 does not simply disarm a tumor. The published abstract reports that in human colorectal cancer, loss of function abolished metastatic seeding while promoting lineage plasticity and non-canonical differentiation into heterogeneous cell states.
In plainer terms, cells that cannot re-enter the stem state do not necessarily stop. Some escape sideways into unusual identities resembling neuroendocrine or squamous cells, states linked in other cancers to treatment resistance and worse outcomes. Depleting protein in primary tumor models slowed growth, but in 5 to 10 percent of patients whose tumors have lost it outright, the cancer tends to make more aggressive adaptations rather than stall.
That turns a straightforward drug-target story into a question of timing and degree. Disrupt the switch decisively and a stressed cell may be unable to adapt. Disrupt it partially or slowly and the result could be selection for something worse.
This is preclinical work. The experiments used mice, patient-derived organoids, and analyses of patient tumor tissue. There is no ZFP36L2-targeting drug, no clinical trial, and nothing a patient can request. Anyone facing colorectal cancer treatment decisions should discuss them with their oncology team.
Regeneration Headlines Get Ahead of the Science
The concept underlying this work is genuinely startling: mature cells are not permanently locked into one identity and can reverse their developmental state when tissue needs rebuilding.
It is also not new in outline. Cellular plasticity in the intestine has been documented for years, including earlier work from the same lab showing that L1CAM marks metastasis-initiating cells that arise from a regenerative program rather than from ordinary tumor stem cells. What the new study contributes is a specific molecular explanation for how the reversal is controlled, which the field had largely lacked.
That distinction matters for reading coverage of this research. Identifying a switch is not the same as being able to flip it safely in a person, and this finding does not mean scientists can regenerate human organs on demand.
Its nearer-term value is as a target. If the protein is what metastasizing cells depend on to survive the stress of colonizing a new organ, it marks a vulnerability at the exact stage that makes colorectal cancer lethal, since metastasis, rather than the original tumor, is what most often kills.
Key Questions Answered
What is ZFP36L2?
An RNA-binding protein that links stress and damage signals in the gut to a cell's ability to change identity. Its activity declines as intestinal cells mature.
What does dedifferentiation mean?
It is the process by which a mature, specialized cell reverts toward an earlier, stem-like state. In the intestine it allows tissue to rebuild its stem cell pool after injury.
How is this connected to cancer spread?
Colorectal cancer cells enter a stressed state when they travel to new organs. They appear to use the same ZFP36L2-dependent program to rewind and start new tumors.
Could blocking this protein treat cancer?
It is a possible target, but the study also found that losing the protein can push cells into atypical states associated with treatment resistance, complicating the approach.
Is any of this available to patients?
No. The work is preclinical, based on mice, organoids, and tumor tissue analysis. No drug or clinical trial targeting this protein exists.
Does this mean organs can be regenerated?
No. The research identifies how a natural repair program is controlled in the intestine. It does not provide a method for regenerating human or
